Press Releases

BrainStorm to Announce Third Quarter Financial Results and Provide Corporate Update on Monday, October 29
Conference Call and Live Webcast at 8:30am Eastern Time

NEW YORK and PETACH TIKVAH, IsraelOct. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the third quarter ended September 30, 2018, and provide a corporate update, on Monday, October 29 at 8:30am Eastern Time.

Monday, October 29, 2018 @ 8:30am Eastern Time
Toll Free: 888-220-8451
Israel Investors: 1809 212 909
International: 323-794-2588
Conference ID: 5255627
Replays, available through November 12, 2018
Toll Free: 844-512-2921
International: 412-317-6671
Conference ID: 5255627

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases.

The Company has developed the NurOwn® technology into a commercially viable product. NurOwn® has been already administered to over 70 patients with ALS in clinical trials conducted in the United States and in Israel. In a randomized, double blind, placebo-controlled clinical trial conducted in the U.S., a clinically meaningful benefit was demonstrated by higher response to NurOwn® compared with placebo. The Company is currently conducting a Phase 3 double blind, placebo-controlled clinical trial at multiple clinical sites throughout the US. For more information, visit the company's website at

Uri Yablonka
Chief Business Officer
BrainStorm Cell Therapeutics Inc.
Phone: (646) 666-3188

Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979



BrainStorm Cell Therapeutics Inc.

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds